Skip to main content
Erschienen in: Pediatric Cardiology 6/2006

01.12.2006 | ORIGINAL ARTICLE

1173C>T Polymorphism in VKORC1 Modulates the Required Warfarin Dose

verfasst von: K. Kosaki, C. Yamaghishi, R. Sato, H. Semejima, H. Fuijita, K. Tamura, K. Maeyama, H. Yamagishi, A. Sugaya, H. Dodo, Y. Tanigawara, T. Takahashi

Erschienen in: Pediatric Cardiology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

The response to warfarin is highly variable among individuals and such variability is likely to have some genetic basis. We evaluted the effect of VKORC1 polymorphisms on warfarin response among Japanese, taking advantage of its unique population structure in which CYP2C9 *2 and *3 alleles are relatively rare. Thirty-one patients (12–34 years old; median, 22) on warfarin were recruited from a pediatric cardiology clinic. Genotyping of the C>T polymorphism at position 1173 in intron 1 of VKORC1 revealed that 26 patients (84%) were T/T homozygotes at nucleotide 1173, whereas 5 (16%) were C/T heterozygotes. Complete linkage disequilibrium was observed between the 1173C > T polymorphism and another polymorphism, the 3730G > A, in the 3′ untranslated region. The C/T heterozyogtes at the 1173C > T polymorphism tended to require more warfarin than the T/T homozygotes, when adjusted for international normalized ratio (p = 0.003). Both the 1173C > T polymorphism and the 3730G > A polymorphism are likely to be inert from a functional standpoint. Rather, based on the complete linkage disequilibrium between 1173C > T and 3730G > A polymorphisms, we suspect that the actual change that defines the relative resistance to warfarin may be present in the proximity of these two polymorphisms.
Literatur
1.
Zurück zum Zitat Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719PubMedCrossRef Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719PubMedCrossRef
2.
Zurück zum Zitat Chenhsu RY, Chiang SC, Chou MH, Lin MF (2000) Long-term treatment with warfarin in Chinese population. Ann Pharmacpther 34:1395–1401 Chenhsu RY, Chiang SC, Chou MH, Lin MF (2000) Long-term treatment with warfarin in Chinese population. Ann Pharmacpther 34:1395–1401
3.
Zurück zum Zitat D’Andrea G, D’Ambrosio RL, Di Perna P, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649PubMedCrossRef D’Andrea G, D’Ambrosio RL, Di Perna P, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649PubMedCrossRef
4.
Zurück zum Zitat Finhn SD, Callahan CM, Martin DC, McDonell MB, Henkoff JG,White RH(1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124:970–979 Finhn SD, Callahan CM, Martin DC, McDonell MB, Henkoff JG,White RH(1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124:970–979
5.
Zurück zum Zitat British Committee for Standard in Hematology (1998) Guidelines on oral anticoagulation: third edition. Br J Haematol 101:34 British Committee for Standard in Hematology (1998) Guidelines on oral anticoagulation: third edition. Br J Haematol 101:34
6.
Zurück zum Zitat Harrington DJ, Underwood S, Morse C, et al. (2005) Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 93:23–26PubMed Harrington DJ, Underwood S, Morse C, et al. (2005) Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 93:23–26PubMed
7.
Zurück zum Zitat James AH, Britt RP, Raskino CL, Thompson SG (1992) Factors affecting the maintenance dose of warfarin. J Clin Pathol 45:704–706PubMed James AH, Britt RP, Raskino CL, Thompson SG (1992) Factors affecting the maintenance dose of warfarin. J Clin Pathol 45:704–706PubMed
9.
Zurück zum Zitat Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacoqenetics 4:39–42CrossRef Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacoqenetics 4:39–42CrossRef
10.
Zurück zum Zitat Rost S, Fregin A, Ivaskevicius V, et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–541PubMedCrossRef Rost S, Fregin A, Ivaskevicius V, et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–541PubMedCrossRef
11.
Zurück zum Zitat Steward DJ, Haining RL, Henne KR, et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361–367PubMedCrossRef Steward DJ, Haining RL, Henne KR, et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361–367PubMedCrossRef
12.
Zurück zum Zitat Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429–439PubMedCrossRef Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429–439PubMedCrossRef
13.
Zurück zum Zitat Takahashi H, Ieiri I, Wilkinson GR, et al. (2004) 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103:3055–3057PubMedCrossRef Takahashi H, Ieiri I, Wilkinson GR, et al. (2004) 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103:3055–3057PubMedCrossRef
14.
Zurück zum Zitat Takahashi H, Wilkinson GR, Caraco Y, et al. (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 13:253–263PubMedCrossRef Takahashi H, Wilkinson GR, Caraco Y, et al. (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 13:253–263PubMedCrossRef
15.
Zurück zum Zitat Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816–1819PubMed Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816–1819PubMed
Metadaten
Titel
1173C>T Polymorphism in VKORC1 Modulates the Required Warfarin Dose
verfasst von
K. Kosaki
C. Yamaghishi
R. Sato
H. Semejima
H. Fuijita
K. Tamura
K. Maeyama
H. Yamagishi
A. Sugaya
H. Dodo
Y. Tanigawara
T. Takahashi
Publikationsdatum
01.12.2006
Erschienen in
Pediatric Cardiology / Ausgabe 6/2006
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-005-1150-x

Weitere Artikel der Ausgabe 6/2006

Pediatric Cardiology 6/2006 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.